Core Insights - The demonstration project of superconducting power transmission by State Grid Shanghai Electric Power Company has been operational for four years, achieving over 35,000 hours of stable operation and delivering nearly 760 million kilowatt-hours of electricity to 49,000 users [1] - This project is the world's largest in terms of transmission capacity, distance, and number of joints, with a total length of 1.2 kilometers and a transmission capacity 4 to 6 times that of conventional cables [1] - The project has led to significant technological breakthroughs and the establishment of industry standards, with over 40 national invention patents and 4 PCT international patents awarded [2] Technological Advancements - The project has developed the world's first full-process pipe-cooling compensation method for superconducting cables, addressing challenges in installation on steep slopes and multiple bends [1] - A real-time monitoring platform for high-temperature superconducting cables has been created, integrating various monitoring functions to ensure reliable operation [2] - The project has successfully implemented a comprehensive inspection system using drones and robotic dogs, enhancing the safety and reliability of superconducting equipment [2] Industry Empowerment and Social Responsibility - The project has established a technical standard system in collaboration with superconducting enterprises, promoting the application of superconducting equipment in power transmission and transformation projects [3] - A science education base for superconducting cables has been certified by two national academic organizations, showcasing China's energy technology innovations and receiving over 4,500 visitors [3] - The project aims to deepen integrated cooperation among industry, academia, and research, fostering collaborative development of science popularization and innovation [3]

Core Viewpoint - Ningbo Jianxin Superconducting Technology Co., Ltd. (stock code: 688805.SH) was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with a closing price of 58.12 yuan, reflecting a 212.81% increase from the opening price [1] Company Overview - Jianxin Superconducting focuses on the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, including superconducting magnets, permanent magnets, and gradient coils, which account for approximately 50% of the cost of MRI equipment [1] - The controlling shareholders are Xu Jianyi, Xu Hui, and Xu Dianbo, who collectively control 59.92% of the voting rights prior to the issuance [1] Shareholding Structure Post-Issue - After the issuance, the controlling shareholders still include Xu Jianyi, Xu Hui, and Xu Dianbo, with their respective holdings reduced to 31.13%, 3.27%, and 3.27% [2] - The total voting rights controlled by these shareholders decreased to 44.94% post-issue [2] Financial Performance - Revenue for Jianxin Superconducting from 2022 to 2024 was 358.93 million yuan, 450.64 million yuan, and 425.50 million yuan, respectively, with net profits of 34.63 million yuan, 48.73 million yuan, and 55.78 million yuan [6] - For the first nine months of 2025, the company reported revenue of 393.30 million yuan, a year-on-year increase of 37.34%, and a net profit of 47.62 million yuan, up 38.54% [10] Future Projections - The company expects to achieve revenue between 580 million yuan and 620 million yuan in 2025, representing a growth of 36.31% to 45.71% compared to 2024 [12] - Projected net profit for 2025 is estimated to be between 72 million yuan and 77 million yuan, indicating a growth of 29.07% to 38.03% [12] Fundraising and Investment Plans - Jianxin Superconducting raised a total of 778.87 million yuan from the issuance, with a net amount of 688.64 million yuan after deducting issuance costs [3] - The funds will be allocated to projects including the annual production of 600 sets of helium-free superconducting magnets and the technological transformation of high-field medical superconducting magnets [5]

12月24日，健信超导登陆上海证券交易所科创板，发行价18.58元/股，开盘价65.03元/股。截至13:59，健信超导股 价报65.73元/股，涨幅达253.77%。 "公司上市既是荣誉，更是责任。资本市场为健信超导提供了更广阔的发展平台，也对公司治理提出了严格要求。 我们将以更高标准强化公司治理，切实维护投资者的长期利益。"健信超导董事长许建益在上市仪式现场说。 许建益表示，上市后，健信超导将坚持以"设计并生产先进的MRI（医用磁共振成像）核心部件和推动磁共振行业 发展"为己任，通过掌握核心技术并持续创新，让磁共振成为大众用得起的日常诊查手段。 同时，健信超导将进一步拓展超导技术的应用范围，让超导技术更好地服务新能源、交通等更广阔的工业领域， 为超导技术的产业化做出更大贡献。 在上海证券交易所上市仪式现场，上海证券交易所副理事长霍瑞戎与健信超导董事长许建益签署证券上市协议。 广发证券副总经理、投行业务管理委员会主任委员胡金泉在上市仪式上表示，健信超导登陆科创板，是企业扎根 行业、厚积薄发的里程碑式跨越，为国内资本市场注入了兼具技术硬实力与成长潜力的优质标的。 "我们相信健信超导将以资本市场为新起点，勇立技 ...

(责任编辑：关婧) 公司的控股股东为许建益，实际控制人为许建益、许卉及许电波。本次发行前，许建益、许卉及许 电波分别直接持有公司41.51%、4.36%及4.36%的股份，许卉通过凯方投资、启益投资分别控制公司 4.84%、4.84%表决权，三人合计控制公司59.92%表决权。其中，许建益系许卉、许电波之父，许电 波、许卉系兄妹关系。 本次发行后，公司的控股股东仍为许建益，实际控制人仍为许建益、许卉及许电波。本次发行后， 许建益、许卉及许电波分别直接持有公司31.13%、3.27%及3.27%的股份，许卉通过凯方投资、启益投 资分别控制公司3.63%、3.63%表决权，三人合计控制公司44.94%表决权。 健信超导本次的募集资金总额为77,887.36万元，扣除发行费用后募集资金净额为68,864.27万元，用 于年产600套无液氦超导磁体项目、年产600套高场强医用超导磁体技改项目、新型超导磁体研发项目。 中国经济网北京12月24日讯 今日，健信超导(688805)在上交所上市。 上交所：健信超导(688805) 健信超导主要从事医用磁共振成像（MRI）设备核心部件的研发、生产和销售，主要产品包括超导 磁体 ...

科创板风险提示 本次发行股票拟在科创板上市，科创板公司具有研发投入大、经营风 险高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投 资者应充分了解科创板的投资风险及本公司所披露的风险因素，审慎作出 投资决定。 宁波健信超导科技股份有限公司 Ningbo Jansen Superconducting Technologies Co., Ltd. （浙江省慈溪高新技术产业开发区高科大道427号） 首次公开发行股票并在科创板上市 招 股 说 明 书 保荐人（主承销商） 广东省广州市黄埔区中新广州知识城腾飞一街 2 号 618 室 宁波健信超导科技股份有限公司 招股说明书 重要声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行 承担股票依法发行后因发行人经营与收益变化或者股 ...

智通财经APP获悉，12月15日，健信超导(688805.SH)开启申购，发行价格为18.58元/股，申购上限为1万股，市盈率 61.97倍，属于上交所，广发证券为其保荐人。 据招股书，公司主要从事医用磁共振成像(MRI)设备核心部件的研发、生产和销售，主要产品包括超导磁体、永磁体和 梯度线圈，占MRI设备核心部件成本的比例在50%左右。公司通过自主研发和持续创新推动磁共振的迭代进步及推广 普及。公司在超导磁体、永磁体和梯度线圈上突破核心技术并实现规模化制造，保障了国产磁共振产业核心部件自主 可控，支撑并推动了国产超导磁共振产业的快速发展，降低医院磁共振检查的价格。 在超导领域，公司已形成包括1.5T零挥发超导磁体、1.5T无液氦超导磁体、3.0T零挥发超导磁体和开放式零挥发超导磁 体在内的丰富产品矩阵，成为全球磁共振行业内排名第一的超导磁体独立供应商。在零挥发超导技术领域，公司追平 了与国际巨头约20年的技术差距，并通过设计和工艺创新持续提升产品性能水平和成本竞争力。公司是国内最早规模 化生产高场强超导磁体的厂商之一，2015年以来，在零挥发超导磁体特别是1.5T产品领域与联影医疗等同步打破了欧 美、日本厂 ...

Core Viewpoint - The company Jianxin Superconductor (688805.SH) has initiated its subscription with an issue price of 18.58 yuan per share and a price-to-earnings ratio of 61.97 times, focusing on the research, production, and sales of core components for MRI equipment, which account for approximately 50% of the cost of MRI devices [1]. Group 1: Company Overview - The company specializes in the research, production, and sales of core components for medical MRI equipment, including superconducting magnets, permanent magnets, and gradient coils [1]. - The company has achieved breakthroughs in core technologies for superconducting magnets, permanent magnets, and gradient coils, ensuring the independence and controllability of core components in the domestic MRI industry [2]. Group 2: Product Development and Market Position - The company has developed a comprehensive product matrix in the superconducting field, including 1.5T and 3.0T zero-evaporation superconducting magnets, becoming the world's leading independent supplier of superconducting magnets [2]. - The company has closed a 20-year technology gap with international giants in zero-evaporation superconducting technology and has broken the long-standing monopoly of European, American, and Japanese manufacturers in the 1.5T product field since 2015 [2]. Group 3: Technological Advancements - The company has transitioned from a follower to a leader in the next-generation helium-free superconducting technology, achieving a fully helium-free superconducting magnet and being recognized as the "international first set of equipment" by the Zhejiang Provincial Economic and Information Technology Department in 2021 [3]. - The company is the largest supplier of MRI permanent magnets globally, providing high-quality products that are economically viable and suitable for grassroots medical systems [3]. Group 4: Financial Performance - The company reported revenues of approximately 359 million yuan, 451 million yuan, 425 million yuan, and 252 million yuan for the years 2022, 2023, 2024, and the first half of 2025, respectively, with net profits of 34.63 million yuan, 48.73 million yuan, 55.78 million yuan, and 31.92 million yuan during the same periods [4]. - As of June 30, 2025, the total assets of the company were approximately 688.99 million yuan, with a debt-to-asset ratio of 29.22% [5].

健信超导扎根医用磁共振成像设备核心部件行业多年，形成了包括1.5T、3.0T及开放式零挥发超导磁体 和1.5T无液氦超导磁体在内丰富的产品矩阵，已成为全球排名第一的超导磁体独立供应商。 尊敬的各位嘉宾、各位投资者朋友： 大家好！ 非常感谢各位参加宁波健信超导科技股份有限公司首次公开发行股票并在上交所科创板上市网上投资者 交流活动。在此，我谨代表广发证券，向大家表示热烈的欢迎及衷心的感谢！ 作为健信超导本次发行上市的保荐人及主承销商，广发证券在与公司长期合作进程中，既见证其稳健快 速发展，亦深切体会到公司管理层具备的超前行业洞察力与深厚的从业经验。我们相信，以本次发行上 市为重要契机，健信超导必将在为国内企业提供更多超导技术国产方案的同时，努力开拓全球市场，开 启高质量发展新篇章。 在今天的网上交流中，我们将认真负责地回答各位投资者和各位朋友提出的问题，让大家能更全面、深 入地了解健信超导，把握投资机会，共享健信超导发展的硕果。欢迎大家踊跃提问，积极参与申购。 最后，预祝健信超导首次公开发行A股圆满成功！谢谢大家！ （文章来源：上海证券报） 在零挥发超导技术领域，公司追平了与国际巨头约20年的技术差距，并通过设 ...

路演嘉宾合影 健信超导：持续自主研发创新努力成为全球磁共振核心部件行业领导品牌 ——宁波健信超导科技股份有限公司首次公开发行股票并在科创板上市网上投资者交流会精彩回放 问：公司的主营业务是什么？ 许建益：公司主要从事医用磁共振成像（MRI）设备核心部件的研发、生产和销售，主要产品包括超导 磁体、永磁体和梯度线圈。公司以"让磁共振成为老百姓用得起的日常诊查手段"为使命，通过自主研发 和持续创新，推动磁共振技术迭代进步及推广普及。 出席嘉宾 宁波健信超导科技股份有限公司董事长许建益先生 宁波健信超导科技股份有限公司董事、总经理姚海锋先生 宁波健信超导科技股份有限公司董事、副总经理、董事会秘书许卉女士 宁波健信超导科技股份有限公司财务总监叶来刚先生 广发证券股份有限公司投行业务管理委员会委员、董事总经理袁海峰先生 广发证券股份有限公司保荐代表人周寅先生 广发证券股份有限公司保荐代表人王振先生 经营篇 问：请介绍公司的产品矩阵。 许建益：公司已形成包括1.5T零挥发超导磁体、1.5T无液氦超导磁体、3.0T零挥发超导磁体和开放式零 挥发超导磁体在内的丰富产品矩阵，成为全球排名第一的超导磁体独立供应商。在零挥发超导技术 ...

Core Viewpoint - Ningbo Jianxin Superconducting Technology Co., Ltd. is set to go public on the Shanghai Stock Exchange's Sci-Tech Innovation Board, aiming to raise funds for various superconducting magnet projects, including the production of 600 sets of helium-free superconducting magnets and medical superconducting magnets [1][4]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 393.30 million yuan, a year-on-year increase of 37.34% [4] - Operating profit reached 53.73 million yuan, up 41.98% year-on-year [4] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, was 47.62 million yuan, reflecting a growth of 38.54% [4] - The growth was driven by increased revenue from helium-free superconducting products and rising domestic demand for medical equipment [4]. Industry Position - Jianxin Superconducting is one of the earliest manufacturers in China to produce high-field superconducting magnets at scale, breaking the long-standing monopoly of European, American, and Japanese companies in the field [4][5]. - The company has achieved a significant technological breakthrough in helium-free superconducting technology, leading to a global first in fully helium-free superconducting magnets [5]. - By 2024, the company is projected to hold the fifth position globally and the second among domestic companies in terms of MRI superconducting magnet market share [5]. Research and Development - As of June 30, 2025, the company holds a total of 85 authorized patents, including 45 invention patents [7]. - Jianxin Superconducting has been recognized as a "Little Giant" enterprise by the national government, indicating its focus on specialized and innovative technologies [7]. - The company is actively involved in various significant R&D projects, including the development of helium-free superconducting magnets and other key technologies [7]. Strategic Partnerships - The company has established close collaborations with renowned MRI equipment manufacturers, including Fujifilm, GE Healthcare, and others, enhancing its supply chain and reducing delivery costs [8]. - Over 50% of the company's products are exported to Japan, Europe, and other emerging markets, facilitating global promotion of MRI equipment [8]. Future Outlook - Jianxin Superconducting aims to deepen its core superconducting technology innovations in the MRI industry and expand its applications into new fields such as power and transportation [9][10]. - The company's vision is to become a leading brand in the global MRI core component industry, focusing on advanced design and production of MRI components [10].